Surgical Innovation Associates
Surgical Innovation Associates is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Surgical Innovation Associates.
Surgical Innovation Associates is a company.
Key people at Surgical Innovation Associates.
Key people at Surgical Innovation Associates.
Surgical Innovation Associates (SIA) is a Chicago-based medical device company developing bioabsorbable scaffolds for general and plastic surgery.[2][4] Its flagship product, SurgiNet, is a polydioxanone mesh designed to improve patient outcomes and reduce systemic healthcare costs through surgeon-led innovations.[1][4] SIA targets surgeons and healthcare systems, addressing challenges in surgical support structures by providing temporary, absorbable scaffolds that eliminate long-term implant complications.[1][4]
The company is FDA-registered as a device establishment, indicating regulatory compliance for manufacturing and listing surgical devices.[2] While specific growth metrics are limited in available data, SIA's focus on "for surgeon, by surgeon" innovation positions it in the growing demand for minimally invasive, cost-effective surgical solutions.[1][5]
Surgical Innovation Associates operates from 445 W Erie St Suite 111, Chicago, IL, with FDA establishment registration under number 3015194982, suggesting establishment around the mid-2010s based on registration patterns for similar entities.[2] Founders and exact inception details are not detailed in public records, but the company's ethos emphasizes surgeon-driven development, likely emerging from clinical needs in general and plastic surgery where permanent meshes cause issues like chronic inflammation or revision surgeries.[1][4]
Early traction includes product development of SurgiNet, a bioabsorbable polydioxanone mesh, and listings on platforms like Wellfound for careers, indicating scaling efforts in talent acquisition.[1] A connection to Anvaya Ventures hints at investment or project support, potentially a pivotal funding moment aiding R&D.[3]
SIA rides the trend toward bioabsorbable implants in medtech, driven by rising minimally invasive surgeries and cost pressures on healthcare systems amid aging populations.[1][4] Timing aligns with post-pandemic emphasis on efficient, outcome-improving devices, as permanent implants face scrutiny for infection risks and revisions—market forces favoring absorbables projected to grow in the $5B+ surgical mesh sector.
By enabling "better outcomes and lower costs," SIA influences the ecosystem through surgeon adoption, potentially accelerating innovation in personalized surgical tools and reducing reliance on foreign implants.[1][5] Its Chicago base taps Midwest medtech hubs, contributing to U.S. manufacturing resurgence.
SIA is poised for expansion as bioabsorbable tech gains traction, with SurgiNet potentially capturing share in plastic and general surgery amid regulatory tailwinds.[4] Upcoming trends like AI-optimized implants and value-based care will shape its path, possibly via partnerships or acquisitions by majors like Integra LifeSciences.[3]
Influence may evolve through broader adoption, scaling from niche scaffolds to platform tech, reinforcing its "for surgeon, by surgeon" edge in a cost-conscious medtech landscape—ultimately delivering on its patient-outcome mission.[1]
